EHA 2016 | The progress of CLL research: towards targeted therapy
Kostas Stamatopoulos
• 9 Jun 2016
Kostas Stamatopoulos, MD, PhD from CERTH Institute of Applied Biosciences, Thessaloniki, Greece discusses the progress of research in chronic lymphocytic leukemia (CLL). Dr Stamatopoulos points out how novel drugs are different from traditional chemotherapy or immunotherapy as they target fundamental processes, which can translate into better response rates and in future, a cure.
Recorded at the at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
